Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link. All three major indices are trading down today with the Dow Jones Industrial Average ( ^DJI) trading down 110 points (-0.7%) at 16,401 as of Tuesday, May 20, 2014, 12:55 PM ET. The NYSE advances/declines ratio sits at 820 issues advancing vs. 2,151 declining with 156 unchanged. The Drugs industry currently sits down 1.1% versus the S&P 500, which is down 0.6%. On the negative front, top decliners within the industry include Vertex Pharmaceuticals ( VRTX), down 1.9%, Mylan ( MYL), down 1.6%, Alexion Pharmaceuticals ( ALXN), down 1.5%, Illumina ( ILMN), down 1.5% and AbbVie ( ABBV), down 1.1%. A company within the industry that increased today was AstraZeneca ( AZN), up 2.3%. TheStreet would like to highlight 3 stocks pushing the industry lower today: 3. Bristol-Myers Squibb Company ( BMY) is one of the companies pushing the Drugs industry lower today. As of noon trading, Bristol-Myers Squibb Company is down $0.49 (-1.0%) to $48.85 on light volume. Thus far, 2.8 million shares of Bristol-Myers Squibb Company exchanged hands as compared to its average daily volume of 8.7 million shares. The stock has ranged in price between $48.81-$49.33 after having opened the day at $49.13 as compared to the previous trading day's close of $49.34. Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. Bristol-Myers Squibb Company has a market cap of $80.8 billion and is part of the health care sector. Shares are down 7.2% year-to-date as of the close of trading on Monday. Currently there are 10 analysts that rate Bristol-Myers Squibb Company a buy, 2 analysts rate it a sell, and 6 rate it a hold. TheStreet Ratings rates Bristol-Myers Squibb Company as a buy. The company's strengths can be seen in multiple areas, such as its impressive record of earnings per share growth, compelling growth in net income, largely solid financial position with reasonable debt levels by most measures, good cash flow from operations and increase in stock price during the past year. Although no company is perfect, currently we do not see any significant weaknesses which are likely to detract from the generally positive outlook. Get the full Bristol-Myers Squibb Company Ratings Report now. STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.